For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260305:nRSE3970Va&default-theme=true
RNS Number : 3970V MicroSalt PLC 05 March 2026
This is a Reach (i.e. non-regulatory) announcement and the information
contained is not
considered to be material or to have a significant impact on management's
expectations of the Company's performance
5 March 2026
MicroSalt Plc
("MicroSalt" or the "Company")
New UK customer
MicroSalt secures Purchase Order with UK-based seasoning manufacturer
MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt
with approximately 50% less sodium, is pleased to announce that it has
received a Purchase Order ("PO") from a new customer, a subsidiary of a
leading European group specialising in natural flavours, colours, and
ingredients, with revenues exceeding €250 million and over 4,200 clients
globally ("Customer").
MicroSalt has been working with this customer for the past 12 months to test
products incorporating MicroSalt's technology. This initial PO is expected to
be followed by further orders and whilst not significant in terms of the
Group's revenue forecasts for 2026 or 2027, the contract represents the
Company's first B2B commercial sale in the UK.
Rick Guiney, Chief Executive Officer of MicroSalt, commented:
"We are excited to partner with a leading player within the UK seasoning
market. This relationship marks a new partner and a new vertical for
MicroSalt, highlighting the continued success of our strategic business model
and the strength of our innovative solutions.
"We look forward to continuing to build on the momentum we have witnessed over
the last few months, establishing and nurturing further relationships with key
players across the sector to drive our mission of proving lower sodium salt
worldwide."
Enquiries:
MicroSalt plc info@microsaltinc.com
Rick Guiney (CEO)
Gracechurch Group (Financial PR) +44 (0)20 4582 3500
Heather Armstrong, Alexis Gore, Rebecca Scott
About MicroSalt
MicroSalt® is disrupting the global salt market with its patented,
full-flavour, low-sodium salt designed for both food manufacturers and
consumers. Using proprietary micron-sized particles, MicroSalt® delivers the
same salty taste as traditional salt with approximately 50% less sodium,
offering a scalable solution to one of the world's most pressing health
challenges. Year to date through 2025, MicroSalt® has contributed to more
than 634M servings made healthier.
Excess sodium consumption is a leading contributor to cardiovascular disease,
the world's number one cause of death. The World Health Organisation has
targeted a 30% reduction in global sodium intake by 2025, a shift projected to
save seven million lives by 2030. The economic case is equally compelling: in
the UK alone, cardiovascular disease costs £19 billion annually, and reducing
average daily salt intake by just one gram could save over 4,000 lives and
£288 million each year.
Operational since 2018, MicroSalt® has established a defensible IP portfolio,
holding a granted US patent and 14 pending applications worldwide. These
protections create significant barriers to entry in a market expected to grow
exponentially as regulation and consumer demand accelerate.
MicroSalt® is ideally positioned for scale and market leadership, with clear
pathways into food manufacturing, consumer channels, and ultimately the
broader £10+ billion global salt market. MicroSalt® is more than a healthier
alternative - it is a disruptive, category-defining solution poised to deliver
significant commercial and societal impact. From January 2025 through February
2026, there have been more than 1 billion servings of food made healthier with
MicroSalt.
For more information, please visit www.microsaltinc.co
(http://www.microsaltinc.co) or follow on X @microSaltPLC.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUPUCGWUPQPUC
Copyright 2019 Regulatory News Service, all rights reserved